Status:
COMPLETED
Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%
Lead Sponsor:
Allergan
Conditions:
Glaucoma
Ocular Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Patients with glaucoma or ocular hypertension currently being treated with latanoprost 0.005%, and in need of additional IOP lowering, will be randomized to receive either bimatoprost 0.03% or travopr...
Eligibility Criteria
Inclusion
- Glaucoma or ocular hypertension in both eyes
- Currently being treated with latanoprost 0.005% daily and in need of additional IOP-lowering
- Best-corrected visual acuity of 20/100 or better in each eye
- Visual field within 6 months of study entry
Exclusion
- Secondary glaucoma
- Active intraocular inflammation or macular edema
- Intraocular surgery or laser surgery within the past 3 months
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2007
Estimated Enrollment :
266 Patients enrolled
Trial Details
Trial ID
NCT00440011
Start Date
August 1 2006
End Date
October 1 2007
Last Update
April 25 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
San Diego, California, United States